Vara receives CE mark for independent second reading in mammography
Breast screening programmes across Europe are under pressure from three directions at once: radiologist shortages, aging populations, and expanded screening age ranges that demand more expert reading time than the workforce can deliver.
Until now, there has been no AI on the market authrised to do what a second radiologist does — read a mammogram independently.
That changed on 15 October 2025. Vara received a new CE certificate for its breast-imaging AI. It is the only AI on the market authorised to operate as an independent second reader, for both screening and diagnostic use. It marks Vara’s entry into the European market.
Why independent reading matters
Most AI in breast screening operates as decision support — a tool that highlights findings for a radiologist to review. An independent second read is fundamentally different. The AI reads the mammogram on its own, the same way a second radiologist would.
This matters because maintaining a human second read is often not economically feasible, particularly in diagnostic workflows. Many programmes simply can’t staff it. An AI that is authorised and clinically validated for that role fills a gap that has been widening for years.
The evidence behind it
This CE mark didn’t happen in a vacuum.
Earlier this year, Nature Medicine published the PRAIM study — initiated by Vara and conducted across 12 screening centres in Germany. It enrolled 460,000 women with no exclusion criteria, making it the largest prospective, real-world study of AI in healthcare.
The results: statistically significant superiority in cancer detection rate and meaningful workload reduction for radiologists.
PRAIM is what made approval for independent second reading possible. Not a retrospective analysis. Not a single-site pilot. A population-wide, prospective study across a national programme.
What regulators recognised beyond performance
In approving Vara’s AI for independent second reading, regulators also recognised something else: Vara’s autonomous, prospective AI monitoring system.
This is the real-time quality assurance infrastructure we’ve written about before — continuous, case-level monitoring of every AI prediction, connected to clinical outcomes. Regulators saw it as setting a new standard for responsible deployment.
Evidence gets you approved. Monitoring is what makes deployment safe.
What’s available, and where
The CE-marked product is available in Europe starting today, as an independent second read or decision support system — including analysis of mammograms from prior screening rounds.
Providers can integrate Vara directly in their PACS viewer, or via the Vara platform. That platform currently serves 40% of the German national screening programme, processing approximately 150,000 mammograms monthly and more than 1.5 million annually.
What this means going forward
Stefan Bunk, co-founder and CTO of Vara:
“Our ambition has always been to pioneer data-driven AI at a nationwide scale. The industry has long moved beyond retrospective evidence. Now, by pairing population-wide, real-world results with automatic real-time monitoring, we’re offering a credible, scalable path for AI in healthcare.”
Europe’s screening capacity challenge isn’t theoretical. It’s here. The question is whether AI can meet the clinical, regulatory, and operational bar required to help.
With the largest prospective evidence base in healthcare AI, the only CE mark for independent second reading, and real-time monitoring built into every deployment — Vara’s answer is yes.
Vara builds AI and cloud workflow tools for breast imaging, helping radiologists detect cancer earlier while reducing unnecessary recalls and reading time